CN1871242A - 作为mch r1拮抗剂用于治疗肥胖症、糖尿病、抑郁症和焦虑的3－(4－(氨基苯基)噻吩并嘧啶－4－酮衍生物 - Google Patents

作为mch r1拮抗剂用于治疗肥胖症、糖尿病、抑郁症和焦虑的3－(4－(氨基苯基)噻吩并嘧啶－4－酮衍生物 Download PDF

Info

Publication number
CN1871242A
CN1871242A CNA2004800313000A CN200480031300A CN1871242A CN 1871242 A CN1871242 A CN 1871242A CN A2004800313000 A CNA2004800313000 A CN A2004800313000A CN 200480031300 A CN200480031300 A CN 200480031300A CN 1871242 A CN1871242 A CN 1871242A
Authority
CN
China
Prior art keywords
compound
formula
phenyl
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800313000A
Other languages
English (en)
Chinese (zh)
Inventor
K·K·巴威安
A·L·翰德伦
D·L·赫特祖格
C·E·海满
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1871242A publication Critical patent/CN1871242A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2004800313000A 2003-10-23 2004-10-21 作为mch r1拮抗剂用于治疗肥胖症、糖尿病、抑郁症和焦虑的3－(4－(氨基苯基)噻吩并嘧啶－4－酮衍生物 Pending CN1871242A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51380003P 2003-10-23 2003-10-23
US60/513,800 2003-10-23

Publications (1)

Publication Number Publication Date
CN1871242A true CN1871242A (zh) 2006-11-29

Family

ID=34549304

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800313000A Pending CN1871242A (zh) 2003-10-23 2004-10-21 作为mch r1拮抗剂用于治疗肥胖症、糖尿病、抑郁症和焦虑的3－(4－(氨基苯基)噻吩并嘧啶－4－酮衍生物

Country Status (15)

Country Link
US (1) US20070078125A1 (2)
EP (1) EP1678184A1 (2)
JP (1) JP2007509158A (2)
KR (1) KR20060100412A (2)
CN (1) CN1871242A (2)
AU (1) AU2004285913A1 (2)
BR (1) BRPI0415667A (2)
CA (1) CA2543122A1 (2)
CO (1) CO5690599A2 (2)
IL (1) IL174693A0 (2)
MA (1) MA28111A1 (2)
MX (1) MXPA06003997A (2)
NO (1) NO20061909L (2)
WO (1) WO2005042541A1 (2)
ZA (1) ZA200603181B (2)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011284A1 (en) * 2005-07-15 2007-01-25 Astrazeneca Ab Therapeutic agents
WO2007039462A2 (en) 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag Indane derivatives as mch receptor antagonists
US7745447B2 (en) * 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
ES2412007T3 (es) 2005-12-21 2013-07-09 Janssen Pharmaceutica, N.V. Derivados de pirazinona sustituida novedosos para uso en enfermedades mediadas por MCH-1
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
DE602007011897D1 (de) * 2006-02-15 2011-02-24 Sanofi Aventis Neue aminoalkohol-substituierte aryldihydroisochinolinone, herstellungsverfahren und ihre verwendung als medikamente
CN101384605A (zh) 2006-02-15 2009-03-11 塞诺菲-安万特股份有限公司 新的氨基醇取代的芳基噻吩并嘧啶酮、其制备方法以及其作为药物的用途
AU2007214709A1 (en) * 2006-02-15 2007-08-23 Sanofi-Aventis Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
BRPI0707869A2 (pt) * 2006-02-15 2011-05-10 Sanofi Aventis ariltienopirimidinonas substituÍdas com azaciclil, processo para a sua preparaÇço e seus usos como medicamentos
CA2652385A1 (en) * 2006-06-08 2007-12-21 Eli Lilly And Company Novel mch receptor antagonists
EP2121703A4 (en) 2006-08-18 2011-12-28 Astrazeneca Ab THIENOPYRIMIDIN-4-ON- AND THIENOPYRIDAZIN-7-ONDERIVATES AS MCH-RL ANTAGONISTS
NZ578096A (en) 2007-01-10 2011-11-25 Albany Molecular Res Inc 5-pyridinone substituted indazoles
JP2010525077A (ja) 2007-04-25 2010-07-22 ブリストル−マイヤーズ スクイブ カンパニー 非塩基性メラニン凝集ホルモン受容体−１アンタゴニスト
ES2382982T3 (es) 2007-07-21 2012-06-15 Albany Molecular Research, Inc. Indazoles sustituidos con 5-piridinona y composiciones farmacéuticas de los mismos
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
US8278316B2 (en) 2009-03-09 2012-10-02 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
HUP1100241A3 (en) 2011-05-06 2013-12-30 Richter Gedeon Nyrt Oxetane substituted pyrimidones
KR20130013199A (ko) * 2011-07-27 2013-02-06 한미약품 주식회사 신규 피리미딘 유도체 및 이를 활성성분으로 포함하는 약학 조성물
JP6283811B2 (ja) 2011-08-26 2018-02-28 オーエヌ ライト サイエンシーズ インコーポレイテッド タトゥ除去システム及び方法
CN115350184A (zh) * 2020-01-10 2022-11-18 康圣博施医药有限公司 药物的治疗组合以及其使用方法
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124627D0 (en) * 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
ZA200603181B (en) 2008-01-30
IL174693A0 (en) 2006-08-20
JP2007509158A (ja) 2007-04-12
AU2004285913A1 (en) 2005-05-12
CO5690599A2 (es) 2006-10-31
CA2543122A1 (en) 2005-05-12
BRPI0415667A (pt) 2006-12-19
NO20061909L (no) 2006-05-03
US20070078125A1 (en) 2007-04-05
EP1678184A1 (en) 2006-07-12
MA28111A1 (fr) 2006-08-01
WO2005042541A1 (en) 2005-05-12
KR20060100412A (ko) 2006-09-20
MXPA06003997A (es) 2006-07-05

Similar Documents

Publication Publication Date Title
CN1253449C (zh) 作为蛋白激酶c抑制剂的吲哚基马来酰亚胺衍生物
CN1240701C (zh) 用作5HT2C激动剂的2,3,4,4a－四氢－1H－吡嗪并(1,2－a)喹喔啉－5(6H)酮衍生物
CN100351236C (zh) 用作5－羟色胺－6配体的1－杂环基烷基－3－磺酰基－吲哚衍生物，其制备方法和用途
CN1214007C (zh) 环戊二烯并吲哚、含有这类化合物的组合物及治疗方法
CN1308311C (zh) 新型吡啶－和喹啉－衍生物
CN1127493C (zh) 苯环的2－位被取代的1－(n－苯氨基烷基)－哌嗪衍生物
CN1165537C (zh) 作为5-ht2c兴奋剂的吡咯并吲哚、吡啶并吲哚和氮杂�并吲哚
CN1163484C (zh) 4-芳酰基-哌啶-ccr-3受体拮抗剂ⅲ
US20030199552A1 (en) Amide derivatives as NMDA receptor antagonists
CN1468217A (zh) 脂肪族含氮五员环化合物
CN1150165C (zh) 用于治疗中枢神经系统紊乱的1-芳基磺酰基-2-芳基-吡咯烷衍生物
CN1327444A (zh) 肾上腺素能α1β受体拮抗药
CN1553910A (zh) 作为5-羟色胺-6配基的杂环基-吲唑或氮杂吲唑化合物
CN1454211A (zh) 作为Xa因子抑制剂的含氮杂双环化合物
CN1468224A (zh) 用作α-2拮抗剂的喹啉衍生物
CN1701068A (zh) 新颖的化合物和它们的用途
CN1608063A (zh) 用作蛋白激酶抑制剂的二氢吲哚酮衍生物
CN1795195A (zh) 新颖的吡啶并吡嗪及其作为激酶调节剂的用途
CN1774433A (zh) 作为胰高血糖素受体拮抗剂的取代的3－氰基噻吩乙酰胺
AU2004285913A1 (en) 3-(4-aminophenyl) thienopyrimid-4-one derivatives as MCH R1 antagonists for the treatment of obesity, diabetes, depression and anxiety
CN1259049A (zh) 可用作5－ht1f激动剂的羧酰胺类
CN1665812A (zh) 用于治疗肥胖的作为选择性黑色素浓缩激素受体拮抗剂的螺取代的哌啶化合物
CN1756753A (zh) 苯并呋喃衍生物
CN1017901B (zh) 抗精神病药稠环吡啶基哌嗪衍生物的制备方法
CN1706824A (zh) 作为ccr5拮抗剂的化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication